SCHEMBL3146949

SCHEMBL3146949

O=CCc1ccnc2ncccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
LOXL2 Q9Y4K0 1/20 0.35
KMT2A Q03164 3/20 0.35
LMNA P02545 3/20 0.35
KDM4E B2RXH2 5/20 0.34
MAPT P10636 2/20 0.34
MEN1 O00255 2/20 0.34
NPC1 O15118 2/20 0.34
HSP90AA1 P07900 2/20 0.34
RAB9A P51151 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
IDO1 P14902 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ERN1 O75460 1/20 0.34
GPR84 Q9NQS5 1/20 0.33
TP53 P04637 2/20 0.33
HTT P42858 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TSHR P16473 1/20 0.33
ALOX12 P18054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9276577 0.81 GABRA1 (0.39) ALDH1A1LOXL2KMT2ALMNAKDM4E
SCHEMBL3397178 0.79 LOXL2 (0.58) ALDH1A1LOXL2KMT2ALMNAKDM4E
SCHEMBL8372588 0.79 GSK3A (0.40) ALDH1A1LOXL2KMT2ALMNAKDM4E
SCHEMBL29954736 0.78 MAPT (0.48) ALDH1A1LOXL2KMT2ALMNAKDM4E
SCHEMBL6878679 0.78 MAPT (0.48) ALDH1A1LOXL2KMT2ALMNAKDM4E
SCHEMBL15415316 0.76 KDM4E (0.53) ALDH1A1LOXL2KMT2ALMNAKDM4E
SCHEMBL3151202 0.75 LOXL2 (0.38) ALDH1A1LOXL2KMT2ALMNAKDM4E
SCHEMBL14995335 0.75 LOXL2 (0.62) LOXL2KMT2ALMNAKDM4EMAPT
SCHEMBL28006255 0.73 CYP1A2 (0.54) KMT2ALMNAKDM4EMAPTMEN1
SCHEMBL4538975 0.73 KDM4E (0.68) KMT2ALMNAKDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7462600-B2 Macrolides PFIZER INC (US) 2008-12-09 US claimed
EP-2233493-A1 Macrolides Pfizer Products Inc. (US) 2010-09-29 EP disclosed
EP-1836211-B1 MACROLIDES PFIZER PROD INC (US) 2010-03-03 EP disclosed
US-7462600-B2 Macrolides PFIZER INC (US) 2008-12-09 US disclosed
EP-1836211-A1 MACROLIDES Pfizer Products Incorporated (US) 2007-09-26 EP disclosed
WO-2006067589-A1 MACROLIDES PFIZER PRODUCTS INC. (US) 2006-06-29 WO disclosed
US-20060135447-A1 Macrolides CHUPAK LOUIS S 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135447-A1 Macrolides LCAT, NOP2, HDAC6 ALDH1A1 3275/4885LOXL2 3991/4885KMT2A 2668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.